References

cardiovascular

Кардиоваскулярная терапия и профилактика

Cardiovascular Therapy and Prevention

1728-88002619-0125

«SILICEA-POLIGRAF» LLC

10.15829/1728-8800-2020-2630

cardiovascular-2630

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020

Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020

https://orcid.org/0000-0002-1095-8787

Гриневич

В. Б.

Grinevich

V. B.

д. м.н., профессор, зав. 2 кафедрой (терапии усовершенствования врачей)

Санкт-Петербург

https://orcid.org/0000-0002-6302-7767

Губонина

И. В.

Gubonina

I. V.

Доктор медицинских наук, профессор, зав. 2 кафедрой (терапии усовершенствования врачей)

Санкт-Петербург

https://orcid.org/0000-0001-8874-4108

Дощицин

В. Л.

Doshchitsin

V. L.

Доктор медицинских наук, профессор кафедры кардиологии

Москва

https://orcid.org/0000-0002-1628-5093

Котовская

Ю. В.

Kotovskaya

Yu. V.

Доктор медицинских наук, профессор, заместитель директора по научной работе ОСП РГНКЦ

Москва

https://orcid.org/0000-0001-8347-0531

Кравчук

Ю. А.

Kravchuk

Yu. A.

Доктор медицинских наук, профессор 2 кафедры (терапии усовершенствования врачей)

Санкт-Петербург

https://orcid.org/0000-0002-3724-7301

Педь

В. И.

Ped

V. I.

Доктор медицинских наук, профессор

Санкт-Петербург

https://orcid.org/0000-0002-8445-8363

Сас

Е. И.

Sas

E. I.

Доктор медицинских наук, профессор

Санкт-Петербург

https://orcid.org/0000-0002-2536-5781

Сыров

А. В.

Syrov

A. V.

Кандидат медицинских наук, зав. отделением кардиологии Консультативно-диагностического центра № 6 ДЗ г. Москвы; кафедра общей врачебной практики РУДН

Москва

https://orcid.org/0000-0003-4277-1711

Тарасов

А. В.

Tarasov

A. V.

Доктор медицинских наук, врач кардиолог-аритмолог; зав. отделением хирургического лечения сложных нарушений ритма сердца

Москва

https://orcid.org/0000-0001-9536-8307

Тарзиманова

А. И.

Tarzimanova

A. I.

Доктор медицинских наук, профессор кафедры факультетской терапии № 2

Москва

tarzimanova@mail.ru

https://orcid.org/0000-0002-4193-688X

Ткачева

О. Н.

Tkacheva

O. N.

Доктор медицинских наук, профессор, директор; главный внештатный гериатр Минздрава России

Москва

https://orcid.org/0000-0002-1597-1876

Трухан

Д. И.

Trukhan

D. I.

Доктор медицинских наук, профессор кафедры поликлинической терапии и внутренних болезней

Омск

Omsk

ФГБВОУ ВО Военно-медицинская Академия им. С. М. Кирова Министерства обороны РФS. M. Kirov Military Medical Academy

ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава РоссииPirogov Russian National Research Medical University

Консультативно-диагностический центр № 6 Департамента Здравоохранения г. Москвы; ФГАОУ ВО Российский университет дружбы народовRUDN University

Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава РоссииNational Medical Research Center for Therapy and Preventive Medicine

ФГАОУ ВО Первый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет)I.M. Sechenov First Moscow State Medical University (Sechenov University)

ОСП Российский геронтологический научно-клинический центр; ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава РоссииPirogov Russian National Research Medical University

ФГБОУ ВО Омский государственный Университет Минздрава РоссииOmsk State University

2020

18062020

19426302630

2020

Гриневич В.Б., Губонина И.В., Дощицин В.Л., Котовская Ю.В., Кравчук Ю.А., Педь В.И., Сас Е.И., Сыров А.В., Тарасов А.В., Тарзиманова А.И., Ткачева О.Н., Трухан Д.И.

Grinevich V.B., Gubonina I.V., Doshchitsin V.L., Kotovskaya Y.V., Kravchuk Y.A., Ped V.I., Sas E.I., Syrov A.V., Tarasov A.V., Tarzimanova A.I., Tkacheva O.N., Trukhan D.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://cardiovascular.elpub.ru/jour/article/view/2630

Пандемия новой коронавирусной инфекции (COVID19), распространяемая вирусом SARS-CoV-2, стала вызовом системам здравоохранения всех стран мира. Коморбидные пациенты являются наиболее уязвимой группой, у которой риск неблагоприятных исходов особенно высок. Проблема ведения коморбидных пациентов в условиях пандемии требует комплексного подхода, направленного как на оптимальное ведение коморбидных состояний у пациентов, которые находятся в условиях самоизоляции, в условиях вынужденных ограничений посещения медицинских учреждений, так и на ведение коморбидных состояний у пациентов, заболевших COVID-19. Представляемый вашему вниманию консенсус охватывает эти два аспекта ведения пациентов с заболеваниями сердечно-сосудистой системы, сахарным диабетом, хронической обструктивной болезнью легких, заболеваниями желудочно-кишечного тракта, а также обращается к полиорганным осложнениям COVID-19.

The pandemic of the novel coronavirus infection (COVID-19), caused by SARS‑CoV‑2, has become a challenge to healthcare systems in all countries of the world. Patients with comorbidity are the most vulnerable group with the high risk of adverse outcomes. The problem of managing these patients in context of a pandemic requires a comprehensive approach aimed both at the optimal management in self-isolated patients not visiting medical facilities, and management of comorbidities in patients with COVID-19. The presented consensus covers these two aspects of managing patients with cardiovascular disease, diabetes, chronic obstructive pulmonary disease, gastrointestinal disease, and also pay attention to the multiple organ complications of COVID-19.

COVID-19коморбидностьпроницаемость барьера слизистой оболочкизаболевания сердечно-сосудистой системыхроническая обструктивная болезнь легкихсахарный диабетболезни органов пищеварения

COVID-19comorbiditypermeability of mucosacardiovascular diseaseschronic obstructive pulmonary diseasediabetesgastrointestinal diseases

References1

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30; Lancet. 2020;395(10223):497‐506. doi:10.1016/S0140-6736(20)30183-5.

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA . 2020 Feb 24. doi:10.1001/jama.2020.2648.

Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899. doi:10.1177/1470320320926899.

Ferrario CM, Jessup J, Gallagher PE, et al. Effects of reninangiotensin system blockage on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:2189-96. doi:10.1111/j.1523-1755.2005.00675.x.

Шляхто Е. В. Конради А. О., Арутюнов Г. П., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):3801. doi:10.15829/1560-4071-2020-3-3801.

Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russ.) doi:10.15829/1560-4071-2020-3-3801.

Временные методические рекомендации Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) версия 7 (03.06.2020) Министерства здравоохранения Российской Федерации. https://www.rosminzdrav.ru/news/2020/06/03/14109-minzdrav-rossii-utverdil-7-versiyumetodicheskih-rekomendatsiy-po-lecheniyu-covid-19

Temporary guidelines for Prevention, diagnosis and treatment of new coronavirus infection (COVID-19) version 7 (03.06.2020) of the Ministry of health of the Russian Federation. (In Russ.) https://www.rosminzdrav.ru/news/2020/06/03/14109-minzdrav-rossii-utverdil-7-versiyumetodicheskih-rekomendatsiy-po-lecheniyu-covid-19

Кобалава Ж. Д., Конради А. О., Недогода С. В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.

Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.

Оганов Р. Г., Симаненков В. И., Бакулин И. Г., и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66. doi:10.15829/1728-8800-2019-1-5-66.

Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.) doi:10.15829/1728-8800-2019-1-5-66.

Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? Journal of Hypertension. 2019;37:1574-86. doi:10.1097/HJH.0000000000002088.

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 16-24 February 2020. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-oncovid-19-final-report.pdf.

Рекомендации ЕSC по диагностике и лечению хронического коронарного синдрома. Российский кардиологический журнал. 2020;25(2):3757. doi:10.15829/1560-4071-2020-2-3757.

2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Russian Journal of Cardiology. 2020;25(2):3757. (In Russ.) doi:10.15829/1560-4071-2020-2-3757.

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://covid19treatmentguidelines.nih.gov.

Gandhi R, Lynch J, del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020. doi:10.1056/NEJMcp2009249.

Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023-6. doi:10.1111/jth.14810.

Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020. doi:10.1056/NEJMoa2012410.

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir — Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382:1787-99. doi:10.1056/NEJMoa2001282/

Bu J, Chen M, Cheng X, et al. Consensus of Chinese experts on diagnosis and treatment processes of acute myocardial infarction in the context of prevention and control of COVID-19 (first edition) Nan Fang Yi Ke Da Xue Xue Bao. 2020;40(2):147-51. doi:10.12122/j.issn.1673-4254.2020.02.01.

Chieffo A, Stefanini GG, Price S, et al. EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic..Eur Heart J. 2020;41(19):1839-51. doi:10.1093/eurheartj/ehaa381.

Mahmud E, Dauerman HL, Welt FG, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic. J Am Coll Cardiol. 2020:S0735-1097(20)35026-9. doi:10.1016/j.jacc.2020.04.039.

Watson RA, Johnson DM, Dharia RN, et al. Anti-Coagulant and Anti-Platelet Therapy in the COVID-19 Patient: A Best Practices Quality Initiative Across a Large Health System. Hosp Pract (1995). 2020. doi:10.1080/21548331.2020.1772639.

Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal 2018;39:213-260. doi:10.1093/eurheartj/ehx419.

Рекомендации ESC по ведению пациентов с острым коронарным синдромом без стойкого подъема сегмента ST. Российский кардиологический журнал. 2016;(3):9-63. doi:10.15829/1560-4071-2016-3-9-63.

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Russian Journal of Cardiology. 2016;(3):9-63. (In Russ.) doi:10.15829/1560-4071-2016-3-9-63.

Рекомендации ESC по ведению пациентов с острым инфарктом миокарды с подъемом сегмента ST. Российский кардиологический журнал 2018;23(5):103-58. doi:10.15829/1560-4071-2018-5-103-158.

The Task Force for the management of acute myocardial infarction in patients presenting with st-segment elevation of the european society of cardiology (ESC) 2017 ESC Guidelines for themanagement of acutemyocardial infarction in patients presenting with ST-segment elevation. Russian Journal of Cardiology. 2018;23(5):103-58. (In Russ.) doi:10.15829/1560-4071-2018-5-103-158.

Guatret P, Lagier J-Ch, Parola P, et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J of Antimi Agents. 2020;105949. doi:10.1016/j.ijantimicag.2020.105949/

Tisdale JE, Jayes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6:479-87. doi:10.1161/CIRCOUTCOMES.113.000152.

January CT, Wann LS, Calkins H. et all. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, Heart Rhythm 2019. doi.org/10.1016/j.hrthm.2019.01.024.

Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал, 2017;(7):7-86. doi:10.15829/1560-4071-2017-7-7-86.

Kirchhof P, Benussi S, Kotecha D, et al. ESC Guidelines for the management of atrial fibrillation developedin collaboration with EACTS. Russian Journal of Cardiology. 2017;(7):7-86. (In Russ.) doi:10.15829/1560-4071-2017-7-7-86.

Фомина И. Г., Тарзиманова А. И., Ветлужский А. В. и др. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. “ПРОМЕТЕЙ” — открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2005;4(4):66-9.

Fomina IG, Tarzimanova AI, Vetluzhsky AV, et al. Propafenone in restoring sinus rhythm in patients with persistent atrial fibrillation. PROMETEY is an open, multicenter, pilot study in the Russian Federation. Cardiovascular therapy and prevention. 2005;4(4):66-9. (In Russ.)

ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance

Caforio ALP, Pankuweit S, Arbustini E, et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48, 2648a-2648d. doi:10.1093/eurheartj/eht210.

Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020:cvaa106. doi:10.1093/cvr/cvaa106.

Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-50. doi:10.1016/j.dsx.2020.03.013.

Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020 May;45(3):230-2. doi:10.1007/s00059-020-04909-z.

Babapoor-Farrokhran S, Gill D, Walker J, et al. Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020;253:117723. doi:10.1016/j.lfs.2020.117723.

Siripanthong B, Nazarian S, Muser D, et al. Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management.Heart Rhythm. 2020:S1547-5271(20)30422-7. doi:10.1016/j.hrthm.2020.05.001.

Sala S, Peretto G, Gramegna M, et al. Acute Myocarditis Presenting as a Reverse Tako-Tsubo Syndrome in a Patient With SARS-CoV-2 Respiratory Infection Eur Heart J. 2020 May 14;41(19):1861-2. doi:10.1093/eurheartj/ehaa286.

Deng Q, Hu B, Zhang Y, et al. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China. Int J Cardiol. 2020:S0167-5273(20)31115-3. doi:10.1016/j.ijcard.2020.03.087.

Kow CS, Hasan SS. Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis. Infection. 2020:1-2. doi:10.1007/s15010-020-01441-4.

Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130(18):1601-6. doi: 10.1161/CIRCULATIONAHA.114.010376.

Cizgici AY, Zencirkiran Agus H, Yildiz M. COVID-19 myopericarditis: It should be kept in mind in today’s conditions Am J Emerg Med. 2020:S0735-6757(20)30310-7. doi: 10.1016/j.ajem.2020.04.080

Tung-Chen Y. Acute pericarditis due to COVID-19 infection: An underdiagnosed disease? Med Clin (Barc). 2020:S0025-7753(20)30257-8. doi:10.1016/j.medcli.2020.04.007.

Khalid N, Chen Y, Case BC, et al. COVID-19 (SARS-Cov-2) and the heart — An ominous association. Cardiovasc Revasc Med. 2020:S1553-8389(20)30256-6. doi:10.1016/j.carrev.2020.05.009.

Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Invest Radiol. 2020 Jun;55(6):327-31. doi:10.1097/RLI.0000000000000672.

Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020:ehaa253. doi:10.1093/eurheartj/ehaa253.

Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; doi:10.1001/jamacardio.2020.1096.

Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020:ehaa253. doi:10.1093/eurheartj/ehaa253.

Рекомендации ESC по диагностике и ведению пациентов с заболеваниями перикарда. Российский кардиологический журнал. 2016;(5):117-62. doi:10.15829/1560-4071-2016-5-117-162.

Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; doi:10.1001/jamacardio.2020.1096.

Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications, European Heart Journal. 2020;41,19:1798-800. doi:10.1093/eurheartj/ehaa231.

Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; doi:10.1001/jamacardio.2020.1096.

Mehra MR, Ruschitzka F. COVID-19 Illness and Heart Failure: A Missing Link? JACC Heart Fail. 2020;8(6):512‐4. doi:10.1016/j.jchf.2020.03.004.

Adler Y., Charron P., Imazio M., et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Russian Journal of Cardiology. 2016;(5):117-62. (In Russ.) doi:10.15829/1560-4071-2016-5-117-162.

HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 https://www.acc.org/latest-incardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statementaddresses-concerns-re-using-raas-antagonists-in-covid-19.

Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020;75(18):2352‐71. doi:10.1016/j.jacc.2020.03.031.

Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications, European Heart Journal. 2020;41,19:1798-800. doi:10.1093/eurheartj/ehaa231.

Llitjos J, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020. doi:10.1111/jth.14869.

Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications, European Heart Journal. 2020;41,19:1798-800. doi:10.1093/eurheartj/ehaa231.

Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020. doi:10.1007/s00134-020-06062-x.

Mehra MR, Ruschitzka F. COVID-19 Illness and Heart Failure: A Missing Link? JACC Heart Fail. 2020;8(6):512‐4. doi:10.1016/j.jchf.2020.03.004.

Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. doi:10.1016/j.thromres.2020.04.013.

Mehra MR, Ruschitzka F. COVID-19 Illness and Heart Failure: A Missing Link? JACC Heart Fail. 2020;8(6):512‐4. doi:10.1016/j.jchf.2020.03.004.

Menter T, Haslbauer J, Nienhold R, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020. doi:10.1111/his.14134.

Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. Journal of the American College of Cardiology. 2020. doi:10.1016/j.jacc.2020.05.001.

PulmCrit — Thrombosis update in COVID-19: Data from the Mount Sinai system in NYC. https://emcrit.org/pulmcrit/sinai/

Ткачева О. Н., Котовская Ю.В, Алексанян Л. А. и др. Согласованная позиция экспертов Российской ассоциации геронтологов и гериатров. Новая коронавирусная инфекция SARS-CoV-2 (COVID19) у пациентов пожилого и старческого возраста: особенности профилактики, диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2020;19(3):2601. doi:10.15829/1728-8800-2020-2601.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Diseas (2020 REPORT). https://goldcopd.org/gold-reports/.

Llitjos J, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020. doi:10.1111/jth.14869.

Adeloye D, Chua S, Lee C, et al; Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015;5(2):020415. doi:10.7189/jogh.05-020415.

Llitjos J, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020. doi:10.1111/jth.14869.

Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941. doi:10.1016/j.rmed.2020.105941.

Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049-57. doi:10.18632/aging.103000.

Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J. 2020;55(5):2000688. doi:10.1183/13993003.00688-2020.

Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. doi:10.1016/j.thromres.2020.04.013.

Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and metaanalysis. J Med Virol. 2020. doi:10.1002/jmv.25889.

Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020. doi:10.1016/j.thromres.2020.04.013.

Gonçalves JMF, Golpe R, García-Talavera I. Chronic obstructive pulmonary disease and SARS-CoV-2 infection. What do we know so far?.Arch Bronconeumol. 2020. doi:10.1016/j.arbres.2020.04.016.

Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society; Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician. Medical Management and Prevention Instruction of Chronic Obstructive Pulmonary Disease During the Coronavirus Disease 2019 Epidemic. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(5):421-6. doi:10.3760/cma.j.cn112147-20200227-00201.

Bhutani M, Hernandez P, Bourbeau J, et al. KEY HIGHLIGHTS of the Canadian Thoracic Society’s Position Statement on the Optimization of Chronic Obstructive Pulmonary Disease Management during the COVID-19 Pandemic. Chest. 2020:S0012-3692(20)31456-2. doi:10.1016/j.chest.2020.05.530.

Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020.03.11.987016. doi:10.1101/2020.03.11.987016.

Временные методические рекомендации “Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 7” (утв. Министерством здравоохранения РФ 03 июня 2020 г.) https://www.rosminzdrav.ru/news/2020/06/03/14109-minzdrav-rossii-utverdil-7-versiyumetodicheskih-rekomendatsiy-po-lecheniyu-covid-19

PulmCrit — Thrombosis update in COVID-19: Data from the Mount Sinai system in NYC. https://emcrit.org/pulmcrit/sinai/

Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective. Chronic Obstr Pulm Dis. 2020;7(2):7375. doi:10.15326/jcopdf.7.2.2020.0149.

PulmCrit — Thrombosis update in COVID-19: Data from the Mount Sinai system in NYC. https://emcrit.org/pulmcrit/sinai/

Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 9-й выпуск (дополненный). Сахарный диабет.2019;22(S1). doi:10.14341/DM221S1

Tkacheva ON, Kotovskaya YuV, Aleksanyan LA, et al. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020;19(3):2601. (In Russ.) doi:10.15829/1728-8800-2020-2601.

Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-50. doi:10.1016/S2213-8587(20)30152-2.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Diseas (2020 REPORT). https://goldcopd.org/gold-reports/.

Трухан Д. И., Викторова И. А., Нефрология. Эндокринология. Гематология. СПб.: СпецЛит, 2017. 253 с.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Diseas (2020 REPORT). https://goldcopd.org/gold-reports/.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3.

Sinclair A, Dhatariya K, Burr O, et al. Guidelines for the management of diabetes in care homes during the Covid-19 pandemic. Diabet Med. 2020. doi:10.1111/dme.14317.

Rayman G, Lumb A, Kennon B, et al. New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic. Diabet Med. 2020 May 17. doi:10.1111/dme.14327.

Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941. doi:10.1016/j.rmed.2020.105941.

Rayman G, Lumb A, Kennon B, et al. Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabet Med. 2020. doi:10.1111/dme.14328.

Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020;167:105941. doi:10.1016/j.rmed.2020.105941.

Эндокринопатии и COVID-19. Неотложные состояния, их профилактика и лечение. Подготовлено ФГБУ “НМИЦ эндокринологии” Минздрава России 21.04.2020. http://edu.rosminzdrav.ru/fileadmin/user_upload/specialists/COVID-19/dop-materials/22.04.2020/EHndokrinopatii_i_COVID-19_21.04.2020.pdf

Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049-57. doi:10.18632/aging.103000.

Fulchand S. Covid-19 and Cardiovascular Disease. BMJ. 2020 May 20;369:m1997. doi:10.1136/bmj.m1997.

Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049-57. doi:10.18632/aging.103000.

Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7:9110. doi: 10.1038/s41598-017-09536-z.

Mao R, Qiu Y, He J-S, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020. Published Online May 12, 2020. doi:10.1016/S2468-1253(20)30126-6.

Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and metaanalysis. J Med Virol. 2020. doi:10.1002/jmv.25889.

Гриневич В. Б., Кравчук Ю. А., Ткаченко Е. И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19. Экспериментальная и клиническая гастроэнтерология. 2020;176(4). doi:10.31146/1682-8658-ecg-176-4.

Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and metaanalysis. J Med Virol. 2020. doi:10.1002/jmv.25889.

Ивашкин В. Т., Зольникова О. Ю., Охлобыстин А. В. и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020:doi:10.22416/1382-4376-2020-30-3-7.

Gonçalves JMF, Golpe R, García-Talavera I. Chronic obstructive pulmonary disease and SARS-CoV-2 infection. What do we know so far?.Arch Bronconeumol. 2020. doi:10.1016/j.arbres.2020.04.016.

Ma C, Cong Y, Zhang H. COVID-19 and the Digestive System. Am J Gastroenterol 2020;00:1-4. doi:10.14309/ajg.0000000000000691.

Gonçalves JMF, Golpe R, García-Talavera I. Chronic obstructive pulmonary disease and SARS-CoV-2 infection. What do we know so far?.Arch Bronconeumol. 2020. doi:10.1016/j.arbres.2020.04.016.

Lin L, Jiang X, Zhang Z, at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. 2020; 69(6):997-1001. doi:10.1136/gutjnl-2020-321013.

Pan L, Mu M, Ren HG, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020. doi:10.14309/ajg.0000000000000620.

Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26(19):2323-32. doi:10.3748/wjg.v26.i19.2323.

Suresh Kumar VC, Mukherjee S, Harne PS, et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. BMJ Open Gastroenterol. 2020;7(1): e000417. doi:10.1136/bmjgast-2020-000417.

Cheung KS, Hung IF, Chan PP. Gastr ointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. Gastroenterology. 2020:S0016-5085(20)30448-0. doi:10.1053/j.gastro.2020.03.065.

Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020.03.11.987016. doi:10.1101/2020.03.11.987016.

Sultan S, Altayar O, Siddique SM. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. 2020:S0016-5085(20)30593-X. doi:10.1053/j.gastro.2020.05.001.

Matsuyama S, Kawase M, Nao N, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. bioRxiv. 2020.03.11.987016. doi:10.1101/2020.03.11.987016.

Parasa S, Desai M, Thoguluva Chandrasekar V, et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Metaanalysis. JAMA Netw Open. — 2020;3(6):e2011335. doi:10.1001/jamanetworkopen.2020.11335.

Temporary guidelines “Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 7” (approved by the Ministry of health of the Russian Federation on June 03, 2020) (In Russ.) https://www.rosminzdrav.ru/news/2020/06/03/14109-minzdrav-rossii-utverdil-7-versiyumetodicheskih-rekomendatsiy-po-lecheniyu-covid-19

Fasano A. All disease begins in the (leaky) gut: role of zonulinmediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020;9:F1000 Faculty Rev-69. Published 2020 Jan 31.

Matysiak-Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 (Suppl. 1):55-62. doi:10.1046/j.1365-2036.18.s1.6.x.

Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective. Chronic Obstr Pulm Dis. 2020;7(2):7375. doi:10.15326/jcopdf.7.2.2020.0149.

Shim S, Jang HS, Myung HW, et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017;15,329:40-7. doi:10.1016/j.taap.2017.05.012.

Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective. Chronic Obstr Pulm Dis. 2020;7(2):7375. doi:10.15326/jcopdf.7.2.2020.0149.

Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-60. doi:10.1007/s10620-017-4871-9.

Algorithms for specialized medical care for patients with diabetes. Edited By I. I. Dedov, M. V. Shestakova, and A. Yu. Mayorov. 9th issue (expanded). Moscow; 2019. (In Russ.) doi:10.14341/DM221S1

Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д.И и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter Pylori заболеваний (VI Московские соглашения). Экспериментальная и клиническая гастроэнтерология. 2017;2:3-21.

Algorithms for specialized medical care for patients with diabetes. Edited By I. I. Dedov, M. V. Shestakova, and A. Yu. Mayorov. 9th issue (expanded). Moscow; 2019. (In Russ.) doi:10.14341/DM221S1

Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70. doi:10.22416/1382-4376-2018-28-1-55-70.

Algorithms for specialized medical care for patients with diabetes. Edited By I. I. Dedov, M. V. Shestakova, and A. Yu. Mayorov. 9th issue (expanded). Moscow; 2019. (In Russ.) doi:10.14341/DM221S1

Каратеев А. Е., Насонов Е. Л., Ивашкин В. Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56:1-29.

100

Лазебник Л. Б., Голованова Е. В., Алексеенко С. А. и др. Рекомендации по профилактике и лечению эзофаго-гастроэнтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология. 2018;151(03):4-18.

101

Ивашкин В. Т., Маев И. В., Царьков П. В. и др. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):49-70. doi:10.22416/1382-4376-2020-30-1-49-70.

102

103

Wen X, Chen X, Zhou X. Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009;34(5):457-60.

104

Yasuda T, Chiba H, Satomi T, et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res. 2012;2(4):e3. Published 2012 Jan 1. doi:10.5037/jomr.2011.2403.

105

Akagi S, Fujiwara T, Nishida M, et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapyinduced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. Published 2019 Jul 25. doi:10.1186/s40780-019-0146-2.

Trukhan DI, Viktorova IA. Nephrology. Endocrinology. Hematology. Saint Petersburg: Spetslit, 2017. 253 p. (In Russ.)

106

Urita Y, Watanabe T, Maeda T, et al. Rebamipide and mosapride enhance pilocarpine-induced salivation. N Am J Med Sci. 2009;1(3):121‐4.

Trukhan DI, Viktorova IA. Nephrology. Endocrinology. Hematology. Saint Petersburg: Spetslit, 2017. 253 p. (In Russ.)

107

Ивашкин В. Т., Маев И. В., Трухманов А. С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(4):75-95. doi:10.22416/1382-4376-2017-27-4-75-95.

Trukhan DI, Viktorova IA. Nephrology. Endocrinology. Hematology. Saint Petersburg: Spetslit, 2017. 253 p. (In Russ.)

108

Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019;14(5):e0216750. doi:10.1371/journal.pone.0216750.

109

Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017;3(11): eaao4966. doi:10.1126/sciadv.aao4966.

110

Мартынов А. И., Шептулин А. А., Маев И. В. и др. Новые возможности цитопротекции в лечении и профилактике заболеваний желудка и кишечника (резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(2):7-14. doi:10.22416/1382-4376-2020-30-2-7-14.

111

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.

Sinclair A, Dhatariya K, Burr O, et al. Guidelines for the management of diabetes in care homes during the Covid-19 pandemic. Diabet Med. 2020. doi:10.1111/dme.14317.

112

Moon AM, Webb GJ, Aloman C, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry [published online ahead of print, 2020 May 21]. J Hepatol. 2020;S0168-8278(20)30305-6. doi:10.1016/j.jhep.2020.05.013.

Sinclair A, Dhatariya K, Burr O, et al. Guidelines for the management of diabetes in care homes during the Covid-19 pandemic. Diabet Med. 2020. doi:10.1111/dme.14317.

113

Walls AC, Park Y-J, Tortorici MA, at al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181,2;281-92.

Sinclair A, Dhatariya K, Burr O, et al. Guidelines for the management of diabetes in care homes during the Covid-19 pandemic. Diabet Med. 2020. doi:10.1111/dme.14317.

114

Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790-6. doi:10.1136/gut.2004.062398.

Rayman G, Lumb A, Kennon B, et al. New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic. Diabet Med. 2020 May 17. doi:10.1111/dme.14327.

115

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020;8,4:420-2. doi:10.1016/S2213-2600(20)30076-X.

Rayman G, Lumb A, Kennon B, et al. New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic. Diabet Med. 2020 May 17. doi:10.1111/dme.14327.

116

Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518-9. doi:10.1053/j.gastro.2020.02.054.

Rayman G, Lumb A, Kennon B, et al. New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic. Diabet Med. 2020 May 17. doi:10.1111/dme.14327.

117

Gao F, Zheng KI, Wang XB, et al. Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients [published online ahead of print, 2020 May 21]. J Gastroenterol Hepatol. 2020;10.1111/jgh.15112. doi:10.1111/jgh.15112.

Rayman G, Lumb A, Kennon B, et al. Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabet Med. 2020. doi:10.1111/dme.14328.

118

Маевская М. В., Надинская М. Ю., Луньков В. Д. и др. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;(6):22-9. doi: 10.22416/1382-4376-2019-29-6-22-29.

Rayman G, Lumb A, Kennon B, et al. Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabet Med. 2020. doi:10.1111/dme.14328.

119

Al-Ani AH, Prentice RE, Rentsch CA, et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020:10.1111/apt.15779.doi:10.1111/apt.15779.

Rayman G, Lumb A, Kennon B, et al. Guidance on the management of Diabetic Ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabet Med. 2020. doi:10.1111/dme.14328.

120

Current Data | Secure-IBD Database. https://covidibd.org/current-data/. Accessed June, 02, 2020

Endocrinopathy and COVID-19. Emergency conditions, their prevention and treatment. Prepared by NMIC endocrinology of the Ministry of health of Russia 21.04.2020 (In Russ.) http://edu.rosminzdrav.ru/fileadmin/user_upload/specialists/COVID-19/dop-materials/22.04.2020/EHndokrinopatii_i_COVID-19_21.04.2020.pdf

121

Ивашкин В. Т., Шелыгин Ю. А., Халиф И. Л., и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;1:6-30.

122

Ивашкин В. Т., Шелыгин Ю. А., Халиф И. Л., и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017;2:7-29.

123

Samanta J, Dhar J, Khaliq A, Kochhar R. 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations. Journal of Digestive Endoscopy. 2020;11(01):13-8. doi:10.1055/s-0040-1712077.

Fulchand S. Covid-19 and Cardiovascular Disease. BMJ. 2020 May 20;369:m1997. doi:10.1136/bmj.m1997.

124

Gastroenterology professional society guidance on endoscopic procedures during the COVID-19 pandemic American Gastroenterological Association. https://gastro.org/practiceguidance/practice-updates/covid-19/gastroenterologyprofessional-society-guidance-on-endoscopic-proceduresduring-the-covid-19-pandemic/ Accessed June 06, 2020.

Fulchand S. Covid-19 and Cardiovascular Disease. BMJ. 2020 May 20;369:m1997. doi:10.1136/bmj.m1997.

125

Kennedy NA, Jones GR, Lamb CA, et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984‐90. doi:10.1136/gutjnl-2020-321244.

Fulchand S. Covid-19 and Cardiovascular Disease. BMJ. 2020 May 20;369:m1997. doi:10.1136/bmj.m1997.

126

Мухаметова Д. Д., Абдулганиева Д. И., Кошкин С. А., и др. Оценка кишечной проницаемости у пациентов с воспалительными заболеваниями кишечника. Лечебное дело. 2016;1:46-51.

Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7:9110. doi: 10.1038/s41598-017-09536-z.

127

Rubin DT, Abreu MT, Rai V, on behalf of the International Organization for the Study of Inflammatory Bowel Disease. Management of Patients with Crohn’s Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology. 2020; doi:10.1053/j.gastro.2020.04.002.

Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7:9110. doi: 10.1038/s41598-017-09536-z.

128

Bezzio C, Saibeni S, Variola A, et al Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020. doi:10.1136/gutjnl-2020-321411.

Wu Q, Zhou L, Sun X, et al. Altered lipid metabolism in recovered SARS patients twelve years after infection. Sci Rep. 2017;7:9110. doi: 10.1038/s41598-017-09536-z.

129

RAND PANEL STATEMENTS Patients with COVID-19 Crohn’s Disease and COVID-19 Ulcerative Colitis. IOIBD Update on COVID19 for Patients with Crohn’s Disease and Ulcerative Colitis. https://ioibd.org/wp-content/uploads/2020/05/RAND-PANELSTATEMENTS.pdf

130

Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020. doi:10.1053/j.gastro.2020.04.012.

131

Ивашкин В. Т., Шелыгин Ю. А., Баранская Е. К., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):76-93. doi:10.22416/1382-4376-2017-27-5-76-93.

132

Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. doi:10.3390/ijerph17051729.

133

Harmer D, Gilbert M, Borman R, Clark K. L. Quantitative mRNA expression profi ling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2020;532:107-10.

134

Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. doi:10.1586/egh.10.25.38–41.

135

Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;21(3):125-6. doi:10.1111/1751-2980.12851.

Grinevich V. B., Kravchuk, A. Yu., Tkachenko E. I., etc. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and clinical gastroenterology. 2020;176(4). (In Russ.) doi:10.31146/1682-8658-ecg-176-4.

136

Szatmary P, Arora A, Raraty MGT, et al. Emerging phenotype of SARS-CoV2 associated pancreatitis., Gastroenterology. 2020. doi:10.1053/j.gastro.2020.05.069.

137

Bruno G, Fabrizio C, Santoro CR, Buccoliero GB. Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-sorare occurrence [published online ahead of print, 2020 Jun 4]. J Med Virol. 2020;10.1002/jmv.26134. doi:10.1002/jmv.26134.

138

Клинические Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению хронического панкреатита. Под ред. Ивашкина В. Т., Маева И. В., Шифрина О. С. и др. М.,2014. 45 с.

Ivashkin VT, Sheptulin AA, Zolnikova OY, et al. New coronavirus infection (COVID-19) and digestive system. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 0 (In Russ.) doi:10.22416/1382-4376-2020-30-3-7.

139

Рекомендации Научного Общества Гастроэнтерологов по диагностике и лечению хронического панкреатита (приняты II съездом НОГР 2 марта 2011 на заседании Российского панкреатологического клуба. Экспериментальная и клиническая медицина. 2011;7:122-9.

140

Хатьков И. Е. Маев И. В., Бордин Д. С., и др. Российский консенсус по диагностике и лечению хронического панкреатита. Терапевтический архив. 2017;2:105-13. doi:10.17116/terarkh 2017 892105-113.

141

Хатьков И. Е. Маев И. В., Бордин Д. С., и др. Российский консенсус по диагностике и лечению хронического панкреатита: акцент на нутритивный статус и вопросы питания. Фарматека. 2016; Гастроэнтерология/гепатология:27-32.

Ma C, Cong Y, Zhang H. COVID-19 and the Digestive System. Am J Gastroenterol 2020;00:1-4. doi:10.14309/ajg.0000000000000691.

142

Хатьков И. Е. Маев И. В., Бордин Д. С., и др. Спорные вопросы российского консенсуса по диагностике и лечению хронического панкреатита. Альманах клинической медицины. 2016;44,6:654-60.

Ma C, Cong Y, Zhang H. COVID-19 and the Digestive System. Am J Gastroenterol 2020;00:1-4. doi:10.14309/ajg.0000000000000691.

143

Ивашкин В. Т., Маев И. В., Охлобыстин А. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению экзокринной недостаточности поджелудочной железы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(2):72-100.

Ma C, Cong Y, Zhang H. COVID-19 and the Digestive System. Am J Gastroenterol 2020;00:1-4. doi:10.14309/ajg.0000000000000691.

144

Hong SJ, Park S-H, Moon JS, et al. Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016;10(6):910-6. doi: 10.5009/gnl15537.

Lin L, Jiang X, Zhang Z, at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. 2020; 69(6):997-1001. doi:10.1136/gutjnl-2020-321013.

145

Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. Digestive diseases and sciences. 2010;55(12):3393-8. doi: 10.1007/s10620-010-1166-9.

Lin L, Jiang X, Zhang Z, at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. 2020; 69(6):997-1001. doi:10.1136/gutjnl-2020-321013.

146

Moon SJ, An JM, Kim J, et al. Pharmacological characterization of rebamipide: its cholecystokinin CCK1 receptor binding profile and effects on Ca2+ mobilization and amylase release in rat pancreatic acinar cells. Eur J Pharmacol. 2004;505(1-3):61‐6. doi:10.1016/j.ejphar.2004.10.032.

Lin L, Jiang X, Zhang Z, at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. 2020; 69(6):997-1001. doi:10.1136/gutjnl-2020-321013.

147

Клинические Рекомендации Российского Общества Хирургов, Ассоциации гепатопанкреатобилиарных хирургов стран СНГ. Острый панкреатит. М., 2015. 38 с.

148

Клинические Рекомендации Российской Ассоциации Эндокринологов. Алгоритмы Специализированной Медицинской Помощи больным Сахарным Диабетом. Под ред. Дедова И. И., Шестаковой М. В., Майрова А. Ю. М., 2017.111 с.

149

Временные рекомендации по ведению больных COVID19 и эндокринными заболеваниями. Под ред. Гринева Е. Н., Халимова Ю. Ш., Бабенко А. Ю. и др. Медицинская Ассоциациея Эндокринологов Санкт-Петербурга, 2020. 9 с.

150

Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26(19):2323-32. doi:10.3748/wjg.v26.i19.2323.

151

Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26(19):2323-32. doi:10.3748/wjg.v26.i19.2323.

152

Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26(19):2323-32. doi:10.3748/wjg.v26.i19.2323.

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

Matysiak-Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 (Suppl. 1):55-62. doi:10.1046/j.1365-2036.18.s1.6.x.

169

Matysiak-Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 (Suppl. 1):55-62. doi:10.1046/j.1365-2036.18.s1.6.x.

170

Matysiak-Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 (Suppl. 1):55-62. doi:10.1046/j.1365-2036.18.s1.6.x.

171

Shim S, Jang HS, Myung HW, et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017;15,329:40-7. doi:10.1016/j.taap.2017.05.012.

172

Shim S, Jang HS, Myung HW, et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017;15,329:40-7. doi:10.1016/j.taap.2017.05.012.

173

Shim S, Jang HS, Myung HW, et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017;15,329:40-7. doi:10.1016/j.taap.2017.05.012.

174

Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-60. doi:10.1007/s10620-017-4871-9.

175

Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-60. doi:10.1007/s10620-017-4871-9.

176

Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-60. doi:10.1007/s10620-017-4871-9.

177

Lazebnik LB, Tkachenko EI, Abdulganieva DI, et al. VI National recommendations for the diagnosis and treatment of aciddependent and associated with Helicobacter Pylori diseases (VI Moscow agreements). Experimental and clinical gastroenterology. 2017;2:3-21. (In Russ.)

178

179

180

Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. (In Russ.) doi:10.22416/1382-4376-2018-28-1-55-70.

181

182

183

Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of non-steroidal anti-inflammatory drugs. Clinical recommendations. Scientific and practical rheumatology. 2018;56:1-29. (In Russ.)

184

Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of non-steroidal anti-inflammatory drugs. Clinical recommendations. Scientific and practical rheumatology. 2018;56:1-29. (In Russ.)

185

Karateev AE, Nasonov EL, Ivashkin VT, et al. Rational use of non-steroidal anti-inflammatory drugs. Clinical recommendations. Scientific and practical rheumatology. 2018;56:1-29. (In Russ.)

186

Lazebnik LB, Golovanova EV, Alekseenko SA, et al. Recommendations for the prevention and treatment of esophago-gastro-enterocolopathies induced by non-steroidal anti-inflammatory drugs. Experimental and clinical gastroenterology. 2018;151(03):4-18 (In Russ.)

187

188

189

Ivashkin VT, Maev IV, Tsar’kov PV, et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(1):49-70. (In Russ.) doi:10.22416/1382-4376-2020-30-1-49-70.

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

Urita Y, Watanabe T, Maeda T, et al. Rebamipide and mosapride enhance pilocarpine-induced salivation. N Am J Med Sci. 2009;1(3):121‐4.

205

Urita Y, Watanabe T, Maeda T, et al. Rebamipide and mosapride enhance pilocarpine-induced salivation. N Am J Med Sci. 2009;1(3):121‐4.

206

Urita Y, Watanabe T, Maeda T, et al. Rebamipide and mosapride enhance pilocarpine-induced salivation. N Am J Med Sci. 2009;1(3):121‐4.

207

Ivashkin VT, Mayev IV, Trukhmanov AS, et al. Diagnostics and treatment of gastroesophageal reflux disease: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):75-95. (In Russ.) doi:10.22416/1382-4376-2017-27-4-75-95.

208

209

210

211

212

213

214

215

216

Martynov AI, Sheptulin AA, Mayev IV, et al. New Prospects of Cytoprotection in the Treatment and Prevention of Gastric and Intestinal Diseases (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):7-14. (In Russ.) doi:10.22416/1382-4376-2020-30-2-7-14.

217

218

219

220

221

222

223

224

225

Walls AC, Park Y-J, Tortorici MA, at al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181,2;281-92.

226

Walls AC, Park Y-J, Tortorici MA, at al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181,2;281-92.

227

Walls AC, Park Y-J, Tortorici MA, at al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181,2;281-92.

228

Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790-6. doi:10.1136/gut.2004.062398.

229

Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790-6. doi:10.1136/gut.2004.062398.

230

Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790-6. doi:10.1136/gut.2004.062398.

231

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020;8,4:420-2. doi:10.1016/S2213-2600(20)30076-X.

232

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020;8,4:420-2. doi:10.1016/S2213-2600(20)30076-X.

233

Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020;8,4:420-2. doi:10.1016/S2213-2600(20)30076-X.

234

Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518-9. doi:10.1053/j.gastro.2020.02.054.

235

Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518-9. doi:10.1053/j.gastro.2020.02.054.

236

Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518-9. doi:10.1053/j.gastro.2020.02.054.

237

238

239

240

Mayevskaya M. V., Nadinskaia M. Y., Lunkov V. D., et al. An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):22-29. (In Russ.) doi: 10.22416/1382-4376-2019-29-6-22-29.

241

242

243

Al-Ani AH, Prentice RE, Rentsch CA, et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020:10.1111/apt.15779.doi:10.1111/apt.15779.

244

Al-Ani AH, Prentice RE, Rentsch CA, et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020:10.1111/apt.15779.doi:10.1111/apt.15779.

245

Al-Ani AH, Prentice RE, Rentsch CA, et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020:10.1111/apt.15779.doi:10.1111/apt.15779.

246

Current Data | Secure-IBD Database. https://covidibd.org/current-data/. Accessed June, 02, 2020

247

Current Data | Secure-IBD Database. https://covidibd.org/current-data/. Accessed June, 02, 2020

248

Current Data | Secure-IBD Database. https://covidibd.org/current-data/. Accessed June, 02, 2020

249

Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical Guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia for the diagnosis and treatment of ulcerative colitis. Coloproctology. 2017;1:6-30. (In Russ.)

250

251

252

Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical Guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia for the diagnosis and treatment of Crohn’s disease. Coloproctology. 2017;2:7-29. (In Russ.)

253

Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical Guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia for the diagnosis and treatment of Crohn’s disease. Coloproctology. 2017;2:7-29. (In Russ.)

254

Ivashkin VT, Shelygin YuA, Khalif IL, et al. Clinical Guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia for the diagnosis and treatment of Crohn’s disease. Coloproctology. 2017;2:7-29. (In Russ.)

255

Samanta J, Dhar J, Khaliq A, Kochhar R. 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations. Journal of Digestive Endoscopy. 2020;11(01):13-8. doi:10.1055/s-0040-1712077.

256

Samanta J, Dhar J, Khaliq A, Kochhar R. 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations. Journal of Digestive Endoscopy. 2020;11(01):13-8. doi:10.1055/s-0040-1712077.

257

Samanta J, Dhar J, Khaliq A, Kochhar R. 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations. Journal of Digestive Endoscopy. 2020;11(01):13-8. doi:10.1055/s-0040-1712077.

258

259

260

261

262

263

264

Muhametova DD, Abdulganieva DI, Koshkin SA, et al. Assessment of intestinal permeability in patients with inflammatory bowel diseases is a Medical matter. 2016;1:46-51. (In Russ.)

265

Muhametova DD, Abdulganieva DI, Koshkin SA, et al. Assessment of intestinal permeability in patients with inflammatory bowel diseases is a Medical matter. 2016;1:46-51. (In Russ.)

266

Muhametova DD, Abdulganieva DI, Koshkin SA, et al. Assessment of intestinal permeability in patients with inflammatory bowel diseases is a Medical matter. 2016;1:46-51. (In Russ.)

267

268

269

270

Bezzio C, Saibeni S, Variola A, et al Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020. doi:10.1136/gutjnl-2020-321411.

271

Bezzio C, Saibeni S, Variola A, et al Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020. doi:10.1136/gutjnl-2020-321411.

272

Bezzio C, Saibeni S, Variola A, et al Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020. doi:10.1136/gutjnl-2020-321411.

273

274

275

276

277

278

279

Ivashkin VT, Shelygin YA, Baranskaya YK, et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93. (In Russ.) doi:10.22416/1382-4376-2017-27-5-76-93.

280

281

282

283

284

285

Harmer D, Gilbert M, Borman R, Clark K. L. Quantitative mRNA expression profi ling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2020;532:107-10.

286

Harmer D, Gilbert M, Borman R, Clark K. L. Quantitative mRNA expression profi ling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2020;532:107-10.

287

Harmer D, Gilbert M, Borman R, Clark K. L. Quantitative mRNA expression profi ling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2020;532:107-10.

288

Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. doi:10.1586/egh.10.25.38–41.

289

Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. doi:10.1586/egh.10.25.38–41.

290

Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. doi:10.1586/egh.10.25.38–41.

291

Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;21(3):125-6. doi:10.1111/1751-2980.12851.

292

Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;21(3):125-6. doi:10.1111/1751-2980.12851.

293

Gao QY, Chen YX, Fang JY. 2019 Novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;21(3):125-6. doi:10.1111/1751-2980.12851.

294

Szatmary P, Arora A, Raraty MGT, et al. Emerging phenotype of SARS-CoV2 associated pancreatitis., Gastroenterology. 2020. doi:10.1053/j.gastro.2020.05.069.

295

Szatmary P, Arora A, Raraty MGT, et al. Emerging phenotype of SARS-CoV2 associated pancreatitis., Gastroenterology. 2020. doi:10.1053/j.gastro.2020.05.069.

296

Szatmary P, Arora A, Raraty MGT, et al. Emerging phenotype of SARS-CoV2 associated pancreatitis., Gastroenterology. 2020. doi:10.1053/j.gastro.2020.05.069.

297

298

299

300

Clinical Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of chronic pancreatitis. Ed. Ivashkin VT, Maev IV, Shifrin OS, et al. 2014. 45 p. (In Russ.)

301

Clinical Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of chronic pancreatitis. Ed. Ivashkin VT, Maev IV, Shifrin OS, et al. 2014. 45 p. (In Russ.)

302

Clinical Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of chronic pancreatitis. Ed. Ivashkin VT, Maev IV, Shifrin OS, et al. 2014. 45 p. (In Russ.)

303

Guidelines Of the scientific society of Gastroenterologists on the diagnosis and treatment of chronic pancreatitis (adopted by the II Congress of the NOGR on March 2, 2011 at a meeting of the Russian pancreatological club. Experimental and clinical medicine. 2011;7:122-9. (In Russ.)

304

305

306

Khatkov IE, Maev IV, Bordin DS, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic archive. 2017;2:105-13. (In Russ.) doi:10.17116/terarkh 2017 892105-113.

307

Khatkov IE, Maev IV, Bordin DS, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic archive. 2017;2:105-13. (In Russ.) doi:10.17116/terarkh 2017 892105-113.

308

Khatkov IE, Maev IV, Bordin DS, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic archive. 2017;2:105-13. (In Russ.) doi:10.17116/terarkh 2017 892105-113.

309

Khatkov IE, Maev IV, Bordin DS, et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis: emphasis on nutritional status and nutrition issues. Pharmateca. 2016; Gastroenterology/Hepatology: 27-32. (In Russ.)

310

311

312

Khatkov IE, Maev IV, Bordin DS, et al. Controversial issues of the Russian consensus on the diagnosis and treatment of chronic pancreatitis. Almanac of clinical medicine. 2016;44,6:654-60. (In Russ.)

313

Khatkov IE, Maev IV, Bordin DS, et al. Controversial issues of the Russian consensus on the diagnosis and treatment of chronic pancreatitis. Almanac of clinical medicine. 2016;44,6:654-60. (In Russ.)

314

Khatkov IE, Maev IV, Bordin DS, et al. Controversial issues of the Russian consensus on the diagnosis and treatment of chronic pancreatitis. Almanac of clinical medicine. 2016;44,6:654-60. (In Russ.)

315

Ivashkin VT, Mayev IV, Okhlobystin AV, et al. Clinical Guidelines of the Russian gastroenterological Association for the diagnosis and treatment of exocrine pancreatic insufficiency. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(2):72-100. (In Russ.)

316

317

318

319

320

321

322

323

324

325

326

327

Clinical Guidelines of the Russian society of Surgeons, Association of hepatopancreatobiliary surgeons of the CIS countries. Acute pancreatitis. Moscow, 2015. 38 p. (In Russ.)

328

Clinical Guidelines of the Russian society of Surgeons, Association of hepatopancreatobiliary surgeons of the CIS countries. Acute pancreatitis. Moscow, 2015. 38 p. (In Russ.)

329

Clinical Guidelines of the Russian society of Surgeons, Association of hepatopancreatobiliary surgeons of the CIS countries. Acute pancreatitis. Moscow, 2015. 38 p. (In Russ.)

330

Clinical Guidelines Of The Russian Association Of Endocrinologists. Algorithms for Specialized Medical Care for patients with Diabetes. Ed. Dedov II, Shestakova MV, Mirova AYu. M. 2017. 111 p. (In Russ.)

331

332

333

Temporary Guidelines for the management of patients with COVID19 and endocrine diseases. Ed. Grineva EN, Khalimov YS, Babenko AYu, et al. Medical Association of Endocrinologists of Saint-Petersburg. 2020, 9 p. (In Russ.)

334

335

The authors declare that there are no conflicts of interest present.